Pfizer Reports 70% Lyme Vaccine Success in Phase 3 Trial as Tick-Borne Risk Spreads
Updated
Updated · Vox.com · Jun 18
Pfizer Reports 70% Lyme Vaccine Success in Phase 3 Trial as Tick-Borne Risk Spreads
1 articles · Updated · Vox.com · Jun 18
Summary
Pfizer said its Phase 3 Lyme disease vaccine cut the risk of developing the illness by more than 70%, both one day after the final dose and one month later.
The company plans to submit the trial data for U.S. approval, potentially adding a new preventive tool as Lyme remains endemic in some communities.
Nearly 500,000 people are estimated to contract Lyme disease each year, while CDC data showed unusually high tick-bite emergency-room visits in late April that kept rising through May and June.
Researchers say black-legged and lone star ticks are expanding into new U.S. regions, driven partly by climate change and land-use shifts, broadening exposure to Lyme disease and alpha-gal syndrome.
Scientists are also pursuing monoclonal antibodies, better diagnostics and eventually a universal anti-tick vaccine, though experts warn vaccine skepticism and federal science funding cuts could slow progress.
A Lyme vaccine is almost here. In an era of scientific distrust, will it be enough to stop the epidemic?
Beyond new drugs, what is the strategy to halt the relentless northward march of disease-carrying ticks?
A single tick bite can now trigger a lifelong meat allergy. Are our public health systems ready?
70%+ Effective Lyme Vaccine from Pfizer/Valneva Heads for 2026 Approval Amid Rising Disease Threat
Overview
Lyme disease remains a major global health concern, with no approved human vaccine available despite its significant burden. This is set to change as the Pfizer/Valneva vaccine candidate has shown promising results in the pivotal Phase 3 VALOR trial. The study enrolled participants aged 5 and older from the US, Canada, and Europe, using a four-dose regimen with a booster timed before peak Lyme season to maximize protection. Initial findings revealed over 70% effectiveness, supporting the vaccine’s strong efficacy and safety profile. These results pave the way for regulatory submission and a potential breakthrough in Lyme disease prevention.